Using induced pluripotent stem cells for modeling Parkinson’s disease

Ke, Minjing; Chong, Cheong-Meng; Su, Huanxing

doi:10.4252/wjsc.v11.i9.634

Cited by 26 publications

(15 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, CTN treatment could potentially play an important role in alleviating neurodegenerative phenotypes in PD patients. However, rodent models may not sufficiently represent the correlation of aging process, genetic factors, and environmental insults in PD patients [ 26 , 27 ]. Thus, it is appropriate to incorporate human-based models that exhibit the complex pathological phenotypes of PD to evaluate the effectiveness of CTN for PD.…”

Section: Introductionmentioning

confidence: 99%

Neuroprotective Effects of Cryptotanshinone in a Direct Reprogramming Model of Parkinson’s Disease

et al. 2020

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a well-known age-related neurodegenerative disease. Considering the vital importance of disease modeling based on reprogramming technology, we adopted direct reprogramming to human-induced neuronal progenitor cells (hiNPCs) for in vitro assessment of potential therapeutics. In this study, we investigated the neuroprotective effects of cryptotanshinone (CTN), which has been reported to have antioxidant properties, through PD patient-derived hiNPCs (PD-iNPCs) model with induced oxidative stress and cell death by the proteasome inhibitor MG132. A cytotoxicity assay showed that CTN possesses anti-apoptotic properties in PD-hiNPCs. CTN treatment significantly reduced cellular apoptosis through mitochondrial restoration, such as the reduction in mitochondrial reactive oxygen species and increments of mitochondrial membrane potential. These effects of CTN are mediated via the nuclear factor erythroid 2-related factor 2 (NRF2) pathway in PD-hiNPCs. Consequently, CTN could be a potential antioxidant reagent for preventing disease-related pathological phenotypes of PD.

show abstract

Section: Introductionmentioning

confidence: 99%

Neuroprotective Effects of Cryptotanshinone in a Direct Reprogramming Model of Parkinson’s Disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…After the discovery of reprogramming technology, research into neurological disorders 42 – 45 and neurodegenerative diseases 46 – 49 initially focused on establishing whether the reprogramming process was equally efficient in cells from healthy individuals and in cells from individuals with disease. The aim of this work was to ensure that hiPSCs would provide a valid system for modelling disease.…”

Section: Switching Gearsmentioning

confidence: 99%

hiPSCs for predictive modelling of neurodegenerative diseases: dreaming the possible

et al. 2021

View full text Add to dashboard Cite

Human induced pluripotent stem cells (hiPSCs) were first generated in 2007, but the full translational potential of this valuable tool has yet to be realized. The potential applications of hiPSCs are especially relevant to neurology, as brain cells from patients are rarely available for research. hiPSCs from individuals with neuropsychiatric or neurodegenerative diseases have facilitated biological and multi-omics studies as well as large-scale screening of chemical libraries. However, researchers are struggling to improve the scalability, reproducibility and quality of this descriptive disease modelling. Addressing these limitations will be the first step towards a new era in hiPSC research — that of predictive disease modelling — involving the correlation and integration of in vitro experimental data with longitudinal clinical data. This approach is a key element of the emerging precision medicine paradigm, in which hiPSCs could become a powerful diagnostic and prognostic tool. Here, we consider the steps necessary to achieve predictive modelling of neurodegenerative disease with hiPSCs, using Huntington disease as an example.

show abstract

“…Similar to AD, the deficit of reliable in vitro models has limited the progression of drug discovery for PD. Several groups obtained iPSCs from patient somatic cells with different genetic mutations including LRRK2, SNCA, PARK2, or PINK1, which are related to familial PD, and the DA neurons derived from iPSCs has been used to investigate the molecular mechanisms (Ke et al, 2019). The dopaminergic neurons derived from LRRK2 iPSCs have some important PD features, including (α-Syn aggregates, overexpression of oxidative stress genes, lower number of neurites, and caspase-3 activation (Nguyen et al, 2011;Sanchez-Danes et al, 2012).…”

Section: Parkinson's Disease (Pd)mentioning

confidence: 99%

Prospects of Directly Reprogrammed Adult Human Neurons for Neurodegenerative Disease Modeling and Drug Discovery: iN vs. iPSCs Models

Zhang

Xie

et al. 2020

Front. Neurosci.

View full text Add to dashboard Cite

A reliable disease model is critical to the study of specific disease mechanisms as well as for the discovery and development of new drugs. Despite providing crucial insights into the mechanisms of neurodegenerative diseases, translation of this information to develop therapeutics in clinical trials have been unsuccessful. Reprogramming technology to convert adult somatic cells to induced Pluripotent Stem Cells (iPSCs) or directly reprogramming adult somatic cells to induced Neurons (iN), has allowed for the creation of better models to understand the molecular mechanisms and design of new drugs. In recent times, iPSC technology has been commonly used for modeling neurodegenerative diseases and drug discovery. However, several technological challenges have limited the application of iN. As evidence suggests, iN for the modeling of neurodegenerative disorders is advantageous compared to those derived from iPSCs. In this review, we will compare iPSCs and iN models for neurodegenerative diseases and their potential applications in the future.

show abstract

Using induced pluripotent stem cells for modeling Parkinson’s disease

Cited by 26 publications

References 122 publications

Neuroprotective Effects of Cryptotanshinone in a Direct Reprogramming Model of Parkinson’s Disease

Neuroprotective Effects of Cryptotanshinone in a Direct Reprogramming Model of Parkinson’s Disease

hiPSCs for predictive modelling of neurodegenerative diseases: dreaming the possible

Prospects of Directly Reprogrammed Adult Human Neurons for Neurodegenerative Disease Modeling and Drug Discovery: iN vs. iPSCs Models

Contact Info

Product

Resources

About